About Us

With an eye on patients™

we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.

Our Leadership

See Bio

Nancy Lurker

Chief Executive Officer & Board Director

Nancy Lurker

Chief Executive Officer & Board Director

Nancy Lurker leads our mission to improve the lives of people facing serious eye disorders. With more than 30 years in the pharmaceutical industry driving scientific and commercial innovation across public and private companies, from start-ups to the Fortune 500, she has a proven track record of maximizing the potential of new therapies and implementing US and global drug launches in diverse therapy areas.

See Bio

Jay Duker, MD

President and Chief Operating Officer

Jay Duker, MD

President and Chief Operating Officer

Jay S. Duker, M.D., leads all clinical development, regulatory affairs, and operations. He is a leading retinal disease expert with more than 30 years in the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical, research, business, start-ups, and academic settings.

See Bio

George O. Elston

Chief Financial Officer

George O. Elston

Chief Financial Officer

Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.

See Bio

Ron Honig, Esq.

Chief Legal Officer & Company Secretary

Ron Honig, Esq.

Chief Legal Officer & Company Secretary

Ron Honig leads in-house counsel, leveraging his more than 30 years of experience in corporate governance, securities law compliance, and mergers and acquisitions to support the Company’s business priorities.

See Bio

Scott Jones

Chief Commercial Officer

Scott Jones

Chief Commercial Officer

Scott Jones leads the commercialization of our innovative ophthalmic products. With significant experience in diverse roles commercializing drugs and devices globally, he is an expert in driving commercialization strategy and navigating healthcare policy.

See Bio

Jennifer Leonard

Chief People Officer & SVP, IT

Jennifer Leonard

Chief People Officer & SVP, IT

Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.

See Bio

Dario Paggiarino, MD

Senior Vice President & Chief Medical Officer

Dario Paggiarino, MD

Senior Vice President & Chief Medical Officer

Dario A. Paggiarino, M.D., leads Company Clinical Development programs and Medical Safety. He is a Medical and Clinical Development expert with more than 35 years of experience with small molecules, biologics and devices/drug-device combinations with focus in advancing therapeutics in the ocular space.

See Bio

Said Saim, PhD

Senior Vice President & Chief Technology Officer

Said Saim, PhD

Senior Vice President & Chief Technology Officer

Said Saim, Ph.D., leads product Research & Development and manufacturing activities. He has more than 30 years of experience across the pharmaceutical industry with responsibilities including R&D and Manufacturing Operations.

See Bio

Isabelle Lefebvre

Chief Regulatory Officer

Isabelle Lefebvre

Chief Regulatory Officer

Isabelle Lefebvre drives the Company’s regulatory strategy and compliance to bring innovative products to patients in the US and around the world. She is a regulatory expert with 30 years of experience across all phases of drug development including ophthalmic and ocular conditions.

See Bio

Michael Pine

Chief Corporate Development & Strategy Officer

Michael Pine

Chief Corporate Development & Strategy Officer

Michael Pine leads inorganic growth and strategy activities. He is an experienced leader in business development, having dedicated more than 20 years to licensing and M&A, advancing commercial, operational, and strategic efforts across both large and small companies in the pharmaceutical industry.

Board of Directors

Göran Ando, MD

Chairman of the Board

Wendy DiCicco

Director

Anthony P. Adamis

Director

David Guyer, MD

Director

John Landis, PhD, MS

Director

Ye (Victor) Liu

Director

Karen Zaderej

Director

Nancy Lurker

Chief Executive Officer & Director

Scientific Advisory Board

Sophie J. Bakri

Sophie J. Bakri, MD, MBA, is Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN and holds the Whitney and Betty MacMillan Professorship in Ophthalmology in Honor of Robert R. Waller, M.D.

David S. Boyer

David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group.

Glenn J. Jaffe

Dr. Jaffe is the Robert Machemer Professor of Ophthalmology and a member of the vitreoretinal faculty at Duke University Eye Center. He is chief of the Retina Division, and founded and directs the Duke Reading Center.

Carl D. Regillo

Board Chair

Dr. Carl D. Regillo is Professor of Ophthalmology at Thomas Jefferson University, Chief of the Retina Service of Wills Eye Hospital and Founder of the Wills Eye Clinical Retina Research Unit in Philadelphia.

Rishi P. Singh

Dr. Rishi P. Singh, MD is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic.

Charles Wykoff

Dr. Charles Wykoff is Managing Partner of the Retina Consultants of Texas Research Centers; Chairman of the Research and Clinical Trials Committee, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.

Anat Loewenstein

Anat Loewenstein, MD, MHA, Professor of Ophthalmology, Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, President of the Israeli Ophthalmological Society and the General Secretary of the Euretina board.